InMed Pharmaceuticals Files 8-K
Ticker: INM · Form: 8-K · Filed: Feb 13, 2025 · CIK: 1728328
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
InMed Pharma dropped an 8-K, likely with financial updates or big news.
AI Summary
InMed Pharmaceuticals Inc. filed an 8-K on February 13, 2025, reporting an event on February 12, 2025. The filing is categorized under Regulation FD Disclosure and Financial Statements and Exhibits. The company is incorporated in British Columbia and its principal executive offices are located in Vancouver, Canada.
Why It Matters
This 8-K filing indicates a regulatory disclosure event for InMed Pharmaceuticals, potentially related to financial statements or significant company news.
Risk Assessment
Risk Level: low — This filing is a standard 8-K for InMed Pharmaceuticals, indicating a routine disclosure rather than a significant event.
Key Numbers
- 001-39685 — Commission File Number (Identifies the company's SEC filing history.)
- 98-1428279 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — Filer
- February 12, 2025 (date) — Earliest event reported
- February 13, 2025 (date) — Date of report
- Vancouver, B.C. Canada (location) — Principal Executive Offices
FAQ
What specific event triggered this 8-K filing?
The filing does not specify the exact event, but it is categorized under Regulation FD Disclosure and Financial Statements and Exhibits, suggesting it relates to company news or financial reporting.
What is the primary business of InMed Pharmaceuticals Inc.?
InMed Pharmaceuticals Inc. is in the business of Pharmaceutical Preparations, as indicated by its Standard Industrial Classification code [2834].
Where are InMed Pharmaceuticals Inc.'s principal executive offices located?
The principal executive offices are located at Suite 1445 - 885 W. Georgia Street, Vancouver, B.C. Canada, V6C 3E8.
What is the company's fiscal year end?
The company's fiscal year ends on June 30.
What is the company's telephone number?
The company's telephone number, including area code, is (604) 669-7207.
Filing Stats: 535 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-02-13 09:38:16
Filing Documents
- ea0230951-8k_inmed.htm (8-K) — 31KB
- ea023095101ex99-1_inmed.htm (EX-99.1) — 213KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-25-013204.txt ( ) — 438KB
- inm-20250212.xsd (EX-101.SCH) — 3KB
- inm-20250212_lab.xml (EX-101.LAB) — 33KB
- inm-20250212_pre.xml (EX-101.PRE) — 22KB
- ea0230951-8k_inmed_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On February 12, 2025, the Company reported financial results for the second quarter of the fiscal year 2025 which ended December 31, 2024. The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 News release, dated February 12, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: February 12, 2025 By: /s/ Eric A Adams Eric A Adams President & CEO 2